Welcome to our dedicated page for Inovio Pharmaceu SEC filings (Ticker: INO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Clinical trial milestones, licensing deals, and cash-burn projections often hide deep inside Inovio’s SEC paperwork. Between a 200-plus page annual report and frequent disclosures of study data, even seasoned biotech investors spend hours hunting for answers. If you’ve ever wondered, “Where can I find Inovio’s quarterly earnings report 10-Q filing?” or searched for “Inovio insider trading Form 4 transactions,” you know the challenge.
Stock Titan’s AI reads every submission to EDGAR the instant it appears, transforming dense documents into clear, actionable summaries. Need the Inovio annual report 10-K simplified? Our AI links each figure to plain-English commentary. Looking for 8-K material events explained after a vaccine data release? Alerts arrive in real time. Form 4 insider transactions real-time updates show exactly when executives buy or sell shares, while our dashboards spotlight cash-runway trends and R&D spend across quarters.
Because Inovio’s business hinges on DNA plasmid technology and regulatory milestones, we connect filing types directly to your questions:
- Which clinical programs advanced this quarter? See the Inovio quarterly earnings report 10-Q filing.
- Did partnership revenue hit its benchmark? Our AI flags those lines for quick review.
- Want alerts on Inovio executive stock transactions Form 4 before data readouts? Notifications appear instantly.
- Need board-level pay details? The latest Inovio proxy statement executive compensation section is summarized and searchable.
Understanding Inovio SEC documents with AI means faster decisions and deeper insights. Get every Inovio SEC filing explained simply—only on Stock Titan.
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company developing DNA medicines and CELLECTRA delivery devices, with lead candidate INO-3107 for recurrent respiratory papillomatosis (RRP). In a completed Phase 1/2 trial of INO-3107, 81.3% of patients experienced a reduction in the number of surgical interventions in the year following treatment versus the year prior.
For the quarter and six months ended June 30, 2025, the company reported net losses of $23.5 million and $43.2 million, respectively, with net loss per share of $0.61 for the quarter and $1.12 year-to-date. Cash and cash equivalents were $24.35 million and short-term investments were $23.20 million (combined $47.5 million). Working capital was $21.0 million, total assets $68.24 million, total stockholders' equity $28.53 million, and accumulated deficit $1.773 billion.
The company disclosed substantial doubt about its ability to continue as a going concern beyond Q2 2026, but closed a July 7, 2025 underwritten public offering that generated $22.5 million of net proceeds. Management resolved a prior manufacturing issue for a CELLECTRA disposable component and completed Design Verification testing.
FAQ
What is the current stock price of Inovio Pharmaceu (INO)?
What is the market cap of Inovio Pharmaceu (INO)?
